Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
Adds response from Shaheen's office in paragraph 5
By Maggie Fick and Ahmed Aboulenein
LONDON/WASHINGTON, July 12 (Reuters) -Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
Novo Nordisk NOVOb.CO will meet with the aides for Senators Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren. In April, the lawmakers wrote to the company expressing alarm at its decision, announced in November, that it would permanently discontinue Levemir by the end of 2024.
Novo said it has given patients enough time to switch to other options, according to a May letter seen by Reuters. The company is unaware of plans for drug manufacturers to produce a biosimilar version of the insulin, the letter said, adding Novo would not assert any patent against such a version.
The sources declined to be named citing the sensitivity of the matter.
It was not clear who from Novo would attend the meeting. A company spokesperson denied there was a meeting scheduled. Shaheen's office confirmed a meeting with Novo was scheduled but declined to provide details.Warnock's and Warren's offices did not respond to a request for comment. Meetings between Congressional aides and company representatives are routine.
The Novo spokesperson said in a statement to Reuters on Friday that Levemir was not discontinued due to "success" of the company's newer medicines Wegovy and Ozempic, widely prescribed for weight loss and part of a new class of drugs called GLP-1 agonists.
When announcing in November the discontinuation of Levemir in the U.S., Novo Nordisk cited manufacturing constraints, reduced patient access and available alternatives -- including its other long-acting insulin Tresiba.
The company said a number of long-acting insulins remained on the market, but experts say it can be inconvenient and stressful for people with diabetes to change insulin regimens
Novo has acknowledged during investor calls at quarterly earnings in the past year that it faces manufacturing capacity limitations for some products as it races to increase production of Wegovy and Ozempic.
The company along with rivals Eli Lilly LLY.N and Sanofi SASY.PA make 100% of all insulin sold in the U.S.
Last year all three companies agreed to cut U.S. list prices for insulin products by up to 75% in 2024, responding to political pressure to make the life-sustaining diabetes treatments more affordable.
Scrutiny of Novo has increased at a time of record profits thanks to commercial success of Wegovy, launched in the U.S. in 2021. Sales of that weight-loss injection propelled the company to the position of Europe's most valuable company worth 587 billion euros ($640 billion).
CEO Lars Jorgensen will testify before the Senate Committee on Health, Education, Labor and Pensions (HELP) in September on the high U.S. costs of Wegovy and Novo's diabetes drug Ozempic.
On Wednesday, Senator Bernie Sanders told Reuters he was confident that Novo can be convinced to cut prices after he publicly shamed the company over how its U.S. prices far surpass those charged in other countries.
Levemir's U.S. sales were 1.27 billion Danish crowns ($185.6 million) in 2023. Sales of Novo's other long-acting insulin Tresiba were 1.33 billion crowns last year.
($1 = 0.9172 euros)
($1 = 6.8419 Danish crowns)
Reporting by Maggie Fick in London and Ahmed Aboulenein in Washington; Editing by David Gregorio
Activos relacionados
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.
